Aptevo Therapeutics Inc. Logo

Aptevo Therapeutics Inc.

Clinical-stage biotech developing antibody-based immunotherapies for cancer.

APVO | US

Overview

Corporate Details

ISIN(s):
US03835L2079
LEI:
Country:
United States of America
Address:
2401 4TH AVE., 98121 SEATTLE

Description

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company specializes in creating bispecific and trispecific antibody-based therapeutics designed to harness a patient's immune system to fight malignancies. Its pipeline includes multiple candidates targeting both hematologic cancers and solid tumors. The lead candidate, Mipletamig, is a CD3 T-cell engager targeting the CD123 tumor antigen for the treatment of Acute Myeloid Leukemia (AML). Other programs in development target various tumor antigens, including PSMA for prostate cancer and Nectin-4 for solid tumors, utilizing mechanisms like T-cell engagement and co-stimulation to enhance anti-tumor activity.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Aptevo Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptevo Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptevo Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Inmolecule Nanotech, S.A. Logo
Develops nanoparticles from plant compounds for biomedical and personal care products.
Spain
MLINA
Inotiv, Inc. Logo
A CRO providing nonclinical drug development services and research models.
United States of America
NOTV
IntegraGen Logo
Provides genomic services for cancer and rare diseases, translating research to practice.
France
ALINT
Intellia Therapeutics, Inc. Logo
A clinical-stage genome editing company developing therapeutics using CRISPR/Cas9.
United States of America
NTLA
InterDigital, Inc. Logo
An R&D company licensing foundational technologies for mobile, video, and AI.
United States of America
IDCC
IntoCell, Inc. Logo
Develops platform technologies for Antibody-Drug Conjugates (ADCs) for oncology.
South Korea
287840
Inventage Lab Inc. Logo
Biopharmaceutical company developing advanced drug delivery systems.
South Korea
389470
Investeko Spolka Akcyjna Logo
Specializes in environmental protection and sustainable business solutions.
Poland
IVE
IQVIA HOLDINGS INC. Logo
Provider of analytics, tech solutions, and clinical research for life sciences.
United States of America
IQV
Isofol Medical Logo
Clinical-stage biotech developing a folate-based therapy to enhance cancer treatments.
Sweden
ISOFOL

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.